Economic aspects of pharmacotherapy for chronic constipation.

Abstract:

:Constipation is one of the most common digestive complaints. It is a symptom, not a disease. The subjectivity that this involves means that assessments of clinical epidemiology, socioeconomic costs and pharmacotherapy are difficult, since there is no definition of 'normal' bowel habit. Although constipation can affect all ages, the problem increases with age, and is of particular concern for those who are frail and in long term care. Cultural influences may affect the prevalence in older people. Drug therapy of constipation cannot be considered in isolation, since there are issues in the prevention of constipation and the principles of good management that also apply. Furthermore, some consideration of the pathophysiology and diagnosis is important. This is because a number of remediable causes can be identified, and the diagnostic process involves patient education, which in turn may be effective in reducing costs. It is the complaint of constipation which leads either to self-medication or to consultation with the medical profession. Both of these courses of action have a significant influence on utilisation of laxatives (cathartics), obtained both over-the-counter and by prescription. Although there are a large number of laxative preparations available, therapy has changed little in half a century. Costs may vary considerably, and with such a significant problem there is a need for comparative studies. However, study methodologies are difficult, and a significant placebo response may be found. Education and preventive measures have been shown to reduce laxative use and costs in institutions. Unfortunately, there are few comparative studies of individual laxatives and even fewer cost-effectiveness studies. Those that there are have been based in institutions, and so extrapolation to other situations may be difficult. In general, little attention is given to constipation. It is, however, an area with significant resource implications in which education and preventive measures have been shown to be beneficial. Even so, there is still a need for good comparative studies, particularly where cost effectiveness is concerned.

journal_name

Pharmacoeconomics

journal_title

PharmacoEconomics

authors

Passmore AP

doi

10.2165/00019053-199507010-00003

subject

Has Abstract

pub_date

1995-01-01 00:00:00

pages

14-24

issue

1

eissn

1170-7690

issn

1179-2027

journal_volume

7

pub_type

杂志文章,评审
  • The value of clopidogrel in addition to standard therapy in reducing atherothrombotic events.

    abstract::The recent multinational, randomised, prospective studies Clopidogrel in Unstable Angina to Prevent Recurrent Events (CURE), Percutaneous Coronary Intervention substudy of CURE (PCI-CURE) and Clopidogrel for the Reduction of Events During Observation (CREDO) have demonstrated the clinical efficacy and safety of clopid...

    journal_title:PharmacoEconomics

    pub_type: 杂志文章,meta分析,多中心研究

    doi:10.2165/00019053-200422004-00006

    authors: Weintraub W,Jönsson B,Bertrand M

    更新日期:2004-01-01 00:00:00

  • Quality of life following a change in therapy for diabetes mellitus.

    abstract:OBJECTIVE:The study objective was to evaluate and compare quality-of-life (QOL) parameters between patients with type 2 (non-insulin-dependent) diabetes mellitus who changed therapy from an oral hypoglycaemic agent (OHA) to insulin and those who remained on an OHA. DESIGN:The World Health Organization Quality of Life ...

    journal_title:PharmacoEconomics

    pub_type: 杂志文章

    doi:10.2165/00019053-199814020-00008

    authors: Pibernik-Okanović M,Szabo S,Metelko Z

    更新日期:1998-08-01 00:00:00

  • Having your cake and eating it: office of fair trading proposal for funding new drugs to benefit patients and innovative companies.

    abstract::There are insufficient resources in the UK to fund all new technologies and new indications approved by the National Institute for Health and Clinical Excellence (NICE). Diverting funding from existing sources will have a detrimental effect on the provision of other priority services. The UK Office of Fair Trading (OF...

    journal_title:PharmacoEconomics

    pub_type: 杂志文章,评审

    doi:10.2165/00019053-200826020-00001

    authors: Godman B,Haycox A,Schwabe U,Joppi R,Garattini S

    更新日期:2008-01-01 00:00:00

  • Modelling the cost effectiveness of cholinesterase inhibitors in the management of mild to moderately severe Alzheimer's disease.

    abstract:OBJECTIVE:To estimate the cost effectiveness (from the UK NHS and personal social services perspective) of the cholinesterase inhibitors donepezil, rivastigmine and galantamine compared with usual care in the treatment of mild to moderately severe Alzheimer's disease. Patients had a mean age of 74 years, a mean disease...

    journal_title:PharmacoEconomics

    pub_type: 杂志文章

    doi:10.2165/00019053-200523120-00010

    authors: Green C,Picot J,Loveman E,Takeda A,Kirby J,Clegg A

    更新日期:2005-01-01 00:00:00

  • Development of an economic model for the management of upper gastrointestinal disease in primary care. Preliminary findings.

    abstract::Health economic models for identifying therapeutic options that maximise health benefits from limited healthcare resources are being developed in a number of therapeutic areas. The development of such a model for upper gastrointestinal (UGI) symptoms to support decision-making by primary care clinicians is of particul...

    journal_title:PharmacoEconomics

    pub_type: 杂志文章,评审

    doi:10.2165/00019053-199814002-00003

    authors: Haycox A,Butterworth M,Walley T,Barton S

    更新日期:1998-01-01 00:00:00

  • The changing environment for US pharmaceuticals.

    abstract::Health reform is currently the predominant health policy issue in the US. It carries profound implications for the pharmaceutical field, including the possibility of price controls that could stifle pharmaceutical research. While policy makers are contemplating alternative approaches to reform, the marketplace for pha...

    journal_title:PharmacoEconomics

    pub_type: 杂志文章

    doi:10.2165/00019053-199400061-00018

    authors: Meyer PR

    更新日期:1994-01-01 00:00:00

  • Economic evaluation of influenza vaccination and economic modelling. Can results be pooled?

    abstract::Scientific reviewing methods were applied to economic studies of influenza vaccination, and an economic model of influenza vaccination was developed from these primary sources. Issues arising from the secondary literature review include the quality of evidence on the effectiveness of the vaccines, the absence of a tra...

    journal_title:PharmacoEconomics

    pub_type: 杂志文章

    doi:10.2165/00019053-199600093-00015

    authors: Jefferson T,Demicheli V

    更新日期:1996-01-01 00:00:00

  • Cost-minimisation study of dorzolamide versus brinzolamide in the treatment of ocular hypertension and primary open-angle glaucoma: in four European countries.

    abstract:OBJECTIVE:Cost is an issue when prescribing two drugs with equivalent efficacy. We compared the direct medical costs of topical brinzolamide 1% (twice a day or three times daily) with topical dorzolamide 2% (twice a day or three times daily) in France, Italy, Portugal and Spain in patients with ocular hypertension or p...

    journal_title:PharmacoEconomics

    pub_type: 临床试验,杂志文章,随机对照试验

    doi:10.2165/00019053-200321030-00005

    authors: Rouland JF,Le Pen C,Gouveia Pinto C,Berto P,Berdeaux G

    更新日期:2003-01-01 00:00:00

  • The impact of incremental innovation in biopharmaceuticals: drug utilisation in original and supplemental indications.

    abstract:BACKGROUND:The apparent decrease in the rate of approval of new molecular entities has provoked extensive discussion and fears that the productivity of biopharmaceutical research and development has severely declined in recent years. OBJECTIVE:To investigate the extent to which traditional measures of innovative outpu...

    journal_title:PharmacoEconomics

    pub_type: 杂志文章

    doi:10.2165/00019053-200624002-00008

    authors: Berndt ER,Cockburn IM,Grépin KA

    更新日期:2006-12-01 00:00:00

  • Cost effectiveness in the treatment of heart failure with ramipril. A Swedish substudy of the AIRE study. Acute Infarction Ramipril Efficacy.

    abstract::We estimated the cost effectiveness of adding the ACE inhibitor ramipril to conventional treatment in patients with heart failure after acute myocardial infarction. These estimates were based on the Acute Infarction Ramipril Efficacy (AIRE) study and on complementary Swedish healthcare resource use data for a subset o...

    journal_title:PharmacoEconomics

    pub_type: 临床试验,杂志文章

    doi:10.2165/00019053-199712020-00016

    authors: Erhardt L,Ball S,Andersson F,Bergentoft P,Martinez C

    更新日期:1997-08-01 00:00:00

  • Direct and indirect costs attributable to alcohol consumption in Germany.

    abstract:AIM:To estimate the direct and indirect costs of morbidity and mortality attributable to alcohol consumption in Germany from a societal perspective in 2002. METHODS:Using the concept of attributable risks and the prevalence-based approach, age- and gender-specific alcohol-attributable fractions for morbidity and morta...

    journal_title:PharmacoEconomics

    pub_type: 杂志文章

    doi:10.2165/00019053-200725070-00006

    authors: Konnopka A,König HH

    更新日期:2007-01-01 00:00:00

  • Formulary management of ACE inhibitors.

    abstract::An increasing number of ACE inhibitors have become available in recent years. Because these agents are all similar, careful scrutiny is required in order to determine specific advantages of particular agents when making formulary decisions. Differences between agents with regard to structure and tissue specificity hav...

    journal_title:PharmacoEconomics

    pub_type: 杂志文章,评审

    doi:10.2165/00019053-199610060-00006

    authors: Gerbrandt KR,Yedinak KC

    更新日期:1996-12-01 00:00:00

  • After 20 Years of Using Economic Evaluation, Should NICE be Considered a Methods Innovator?

    abstract::The National Institute for Health and Care Excellence (NICE) is only one of several organisations internationally that uses economic evaluation as part of decision making regarding funding and pricing of new medical technologies. However, it can be argued that NICE has developed a more prominent international profile ...

    journal_title:PharmacoEconomics

    pub_type: 杂志文章

    doi:10.1007/s40273-019-00882-6

    authors: Sculpher M,Palmer S

    更新日期:2020-03-01 00:00:00

  • Interferon-beta in multiple sclerosis. Can we control its costs?

    abstract::The recent licensing of interferon-beta for use in patients with multiple sclerosis has caused concern, in view of the equivocal evidence of efficacy, pressure of public expectation towards its use and the high expected cost if widespread use were to be sanctioned. Whether such alarm is justified remains a moot point....

    journal_title:PharmacoEconomics

    pub_type: 杂志文章

    doi:10.2165/00019053-199711030-00002

    authors: Tolley KH,Whynes DK

    更新日期:1997-03-01 00:00:00

  • A Case Study Examining the Usefulness of Cure Modelling for the Prediction of Survival Based on Data Maturity.

    abstract:INTRODUCTION:Mixture modelling is increasingly being considered where a potential cure leads to a long life. Traditional methods use relative survival models for frail populations or cure models that have improper survival functions with theoretical infinite lifespans. Additionally, much of the work uses population dat...

    journal_title:PharmacoEconomics

    pub_type: 杂志文章

    doi:10.1007/s40273-019-00867-5

    authors: Grant TS,Burns D,Kiff C,Lee D

    更新日期:2020-04-01 00:00:00

  • How Qualitative Methods Can be Used to Inform Model Development.

    abstract::Decision-analytic models play a key role in informing healthcare resource allocation decisions. However, there are ongoing concerns with the credibility of models. Modelling methods guidance can encourage good practice within model development, but its value is dependent on its ability to address the areas that modell...

    journal_title:PharmacoEconomics

    pub_type: 杂志文章

    doi:10.1007/s40273-017-0499-z

    authors: Husbands S,Jowett S,Barton P,Coast J

    更新日期:2017-06-01 00:00:00

  • Replicating Health Economic Models: Firm Foundations or a House of Cards?

    abstract::Health economic evaluation is a framework for the comparative analysis of the incremental health gains and costs associated with competing decision alternatives. The process of developing health economic models is usually complex, financially expensive and time-consuming. For these reasons, model development is someti...

    journal_title:PharmacoEconomics

    pub_type: 杂志文章

    doi:10.1007/s40273-017-0553-x

    authors: Bermejo I,Tappenden P,Youn JH

    更新日期:2017-11-01 00:00:00

  • Per-patient-per-month drug costs in Medicare Part D protected classes.

    abstract:OBJECTIVE:The objective of this study was to estimate the per-patient-per-month (PPPM) costs of medications in the six Medicare Part D protected classes based on findings among Medicare and dual eligible beneficiaries with drug coverage before the enactment of the benefit. DESIGN:Data were from the Thomson Medstat Mar...

    journal_title:PharmacoEconomics

    pub_type: 杂志文章

    doi:10.2165/00019053-200624003-00007

    authors: Mucha L,Masia NA,Axelsen KJ

    更新日期:2006-01-01 00:00:00

  • Critical leg ischaemia in New Zealand: economic cost of amputation versus intravenous iloprost.

    abstract::The purpose of this study was to establish the incidence of surgical amputation for critical leg ischaemia in New Zealand, and estimate the hospital, prostheses and indirect costs of this intervention. The cost of amputations was then compared with the cost of treating such patients with iloprost. The study was retr...

    journal_title:PharmacoEconomics

    pub_type: 杂志文章

    doi:10.2165/00019053-199406020-00007

    authors: Scott HM,Scott WG

    更新日期:1994-08-01 00:00:00

  • An historical survey of UK government measures to control the NHS medicines expenditure from 1948 to 1996.

    abstract::Since the inception of the National Health Service in 1948, successive British governments have taken various measures to restrain the growth of the medicines bill. A total of 10 different measures have been introduced with very limited success. The most effective measures have been those directed at increasing the le...

    journal_title:PharmacoEconomics

    pub_type: 杂志文章,评审

    doi:10.2165/00019053-199610030-00003

    authors: Griffin JP

    更新日期:1996-09-01 00:00:00

  • Statistical versus quantitative significance in the socioeconomic evaluation of medicines.

    abstract::This article examines the twin concepts of the statistical significance and quantitative importance of observed differences in studies comparing medicines in terms of economic parameters such as cost-effectiveness and measures of health-related quality of life (HRQOL). Central to the design and interpretation of any ...

    journal_title:PharmacoEconomics

    pub_type: 杂志文章,评审

    doi:10.2165/00019053-199405050-00005

    authors: O'Brien BJ,Drummond MF

    更新日期:1994-05-01 00:00:00

  • Mapping PROMIS Global Health Items to EuroQol (EQ-5D) Utility Scores Using Linear and Equipercentile Equating.

    abstract:BACKGROUND:Mapping Patient-Reported Outcomes Measurement Information System-Global Health (PROMIS-GH) to EuroQol 5-dimension, three-level version (EQ-5D-3L) provides a utility score for use in quality-of-life and cost-effectiveness analyses. In 2009, Revicki et al. mapped the PROMIS-GH items to EQ-5D-3L utilities using...

    journal_title:PharmacoEconomics

    pub_type: 杂志文章

    doi:10.1007/s40273-017-0541-1

    authors: Thompson NR,Lapin BR,Katzan IL

    更新日期:2017-11-01 00:00:00

  • An economic analysis of the Survival and Ventricular Enlargement (SAVE) Study. Application to the United Kingdom.

    abstract::Recent studies have shown that ACE inhibitors reduce morbidity and mortality after myocardial infarction (MI). While these trials have obvious clinical implications, the widespread introduction of a new treatment for a condition as common as MI also has clear cost implications. The results of the post-MI studies with ...

    journal_title:PharmacoEconomics

    pub_type: 临床试验,杂志文章

    doi:10.2165/00019053-199712020-00008

    authors: Hummel S,Piercy J,Wright R,Davie A,Bagust A,McMurray J

    更新日期:1997-08-01 00:00:00

  • Cost evaluation of basiliximab treatment for renal transplant patients in Japan.

    abstract:BACKGROUND:International phase III studies (CHIB 201 and 352) showed that basiliximab, a high affinity chimeric monoclonal antibody interleukin-2 receptor antagonist, is highly effective in preventing acute rejection when used as immunoprophylaxis in patients receiving cyclosporin (Neoral). We conducted a cost evaluati...

    journal_title:PharmacoEconomics

    pub_type: 临床试验,杂志文章,随机对照试验

    doi:10.2165/00019053-200321110-00003

    authors: Hasegawa T,Imai H,Miki S

    更新日期:2003-01-01 00:00:00

  • Common Problems, Common Data Model Solutions: Evidence Generation for Health Technology Assessment.

    abstract::There is growing interest in using observational data to assess the safety, effectiveness, and cost effectiveness of medical technologies, but operational, technical, and methodological challenges limit its more widespread use. Common data models and federated data networks offer a potential solution to many of these ...

    journal_title:PharmacoEconomics

    pub_type: 杂志文章

    doi:10.1007/s40273-020-00981-9

    authors: Kent S,Burn E,Dawoud D,Jonsson P,Østby JT,Hughes N,Rijnbeek P,Bouvy JC

    更新日期:2020-12-18 00:00:00

  • What's good and bad about contraceptive products?: a best-worst attribute experiment comparing the values of women consumers and GPs.

    abstract:BACKGROUND:In the past decade, the range of contraceptives available has increased dramatically. There are limited data on the factors that determine women's choices on contraceptive alternatives or what factors providers consider most important when recommending contraceptive products to women. OBJECTIVES:Our objecti...

    journal_title:PharmacoEconomics

    pub_type: 杂志文章

    doi:10.2165/11598040-000000000-00000

    authors: Knox SA,Viney RC,Street DJ,Haas MR,Fiebig DG,Weisberg E,Bateson D

    更新日期:2012-12-01 00:00:00

  • Economic value of thrombolysis with adjunctive abciximab in patients with subacute peripheral arterial occlusion.

    abstract:BACKGROUND AND OBJECTIVE:Glycoprotein (GP) IIb/IIIa receptor inhibitors enhance thrombolysis in patients with acute coronary syndromes. This analysis evaluates the economic impact of abciximab, a GP IIb/IIIa inhibitor, as an adjunct to urokinase in peripheral artery occlusions of less than 6 weeks duration. STUDY DESI...

    journal_title:PharmacoEconomics

    pub_type: 临床试验,杂志文章,随机对照试验

    doi:10.2165/00019053-200220030-00006

    authors: Duda SH,Tepe G,Bala M,Luz O,Ziemer G,Ouriel K,Pusich B,Wiskirchen J,Claussen CD,Banz K

    更新日期:2002-01-01 00:00:00

  • Discrete Choice Experiments in Health Economics: Past, Present and Future.

    abstract:OBJECTIVES:Discrete choice experiments (DCEs) are increasingly advocated as a way to quantify preferences for health. However, increasing support does not necessarily result in increasing quality. Although specific reviews have been conducted in certain contexts, there exists no recent description of the general state ...

    journal_title:PharmacoEconomics

    pub_type: 杂志文章

    doi:10.1007/s40273-018-0734-2

    authors: Soekhai V,de Bekker-Grob EW,Ellis AR,Vass CM

    更新日期:2019-02-01 00:00:00

  • The Cost Effectiveness of Docetaxel and Active Symptom Control versus Active Symptom Control Alone for Refractory Oesophagogastric Adenocarcinoma: Economic Analysis of the COUGAR-02 Trial.

    abstract:BACKGROUND:The COUGAR-02 trial recently showed survival and quality-of-life benefits of docetaxel and active symptom control (DXL + ASC) over active symptom control (ASC) alone in patients with refractory oesophagogastric adenocarcinoma. AIM:The aim of this study was to conduct an economic evaluation conforming to Nat...

    journal_title:PharmacoEconomics

    pub_type: 杂志文章

    doi:10.1007/s40273-015-0324-5

    authors: Meads DM,Marshall A,Hulme CT,Dunn JA,Ford HE

    更新日期:2016-01-01 00:00:00

  • Durvalumab for the Treatment of Locally Advanced, Unresectable, Stage III Non-Small Cell Lung Cancer: An Evidence Review Group Perspective of a NICE Single Technology Appraisal.

    abstract::As part of the Single Technology Appraisal (STA) process, the National Institute for Health and Care Excellence (NICE) invited the manufacturer (AstraZeneca) of durvalumab (IMFINZITM) to submit evidence for the clinical and cost effectiveness of durvalumab for the treatment of patients with locally advanced, unresecta...

    journal_title:PharmacoEconomics

    pub_type: 杂志文章,评审

    doi:10.1007/s40273-019-00870-w

    authors: Witlox WJA,van Asselt ADI,Wolff R,Armstrong N,Worthy G,Chalker A,Buksnys T,Stirk L,Kleijnen J,Joore MA,Grimm SE

    更新日期:2020-04-01 00:00:00